Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1092
- Registration Number
- NCT02321878
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes
- Interventions
- Other: No treatment given
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 7315
- Registration Number
- NCT02306681
- Locations
- 🇦🇪
Novo Nordisk Investigational Site, Ajman, United Arab Emirates
Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- Drug: insulin 338 (GIPET I)
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 45
- Registration Number
- NCT02304627
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 397
- Registration Number
- NCT02305381
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Presov, Slovakia
Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects
Phase 1
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: placebo
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 54
- Registration Number
- NCT02300844
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 420
- Registration Number
- NCT02298192
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Zilina, Slovakia
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1788
- Registration Number
- NCT02255266
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Rome, Italy
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 308
- Registration Number
- NCT02254291
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan
Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 54
- Registration Number
- NCT02249871
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects
Phase 1
Completed
- Conditions
- HealthyDiabetes
- Interventions
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT02249910
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath